|Awarded On||August 19, 2020|
|Title||A Hippo Pathway Sensitized Genetic Screen for Regulators of Yap/Taz Driven Hepatocellular Carcinoma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Guillermina Lozano|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
*Pending contract negotiation
Hepatocellular carcinoma (HCC) is a critical public health issue in the United States and especially in Texas due to in part from a growing epidemic of non-alcoholic fatty liver disease (NAFLD). It is estimated that 30% of the population have NAFLD and these individuals are at increased risk to develop more serious conditions such as non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). In the United States it is estimated that in 2017 that there were 27,000 liver cancer related deaths. In Texas, liver cancers accounted for approximately 5% of all cancer related deaths in 2018 and from 2011-2015 was the fourth leading cause of cancer related deaths in men and the seventh l...